

TABLE 1:  
TRP targeting molecules

Category	Description	Example assets
Small molecule	<ul style="list-style-type: none"><li>• Lower affinity for target and greater possibility of off-target effects</li><li>• Easy to manufacture</li><li>• Good tumor penetration</li><li>• Effective despite lower radionuclide to target ratios</li><li>• Rapid pharmacokinetics accommodates a broader range of radionuclides</li><li>• Generally easiest to penetrate the blood brain barrier (BBB)</li></ul>	<ul style="list-style-type: none"><li>• [68Ga] FAPI-46 PET</li><li>• Detectnet</li><li>• Technetium Tc-99m tilmanocept</li></ul>
Peptide	<ul style="list-style-type: none"><li>• High affinity for target</li><li>• Good tumor penetration</li><li>• Flexible design, highly tunable pharmacokinetics</li><li>• Typically require transport mechanisms to cross BBB</li></ul>	<ul style="list-style-type: none"><li>• Pluvicto</li><li>• Lutathera</li><li>• RYZ101</li></ul>
(Mini) antibody, antibody fragments	<ul style="list-style-type: none"><li>• High affinity for target</li><li>• Potential for multiple chelators (and radionuclides) per targeting agent</li><li>• Slower pharmacokinetics can impact radionuclide considerations</li><li>• Typically require transport mechanisms to cross BBB</li></ul>	<ul style="list-style-type: none"><li>• TLX591</li><li>• Iomab-B</li></ul>

TABLE 2:  
Radionuclides

Particle type	Description	Example radionuclide
Alpha ( $\alpha$ )	<ul style="list-style-type: none"><li>• Greater potency; more likely to cause double-stranded DNA breaks</li><li>• Shorter penetration distance, potentially requiring more homogeneous antigen expression</li><li>• Used almost exclusively in therapeutics</li></ul>	<ul style="list-style-type: none"><li>• Actinium-225 (Ac-225)</li></ul>
Beta ( $\beta$ )	<ul style="list-style-type: none"><li>• Moderate penetration ability and ionization power; more likely to cause single-stranded DNA breaks</li><li>• Larger penetration distance, permitting more heterogeneous antigen expression</li><li>• Used primarily in therapeutics</li></ul>	<ul style="list-style-type: none"><li>• Lutetium-177 (Lu-177)</li></ul>
Gamma ( $\gamma$ )	<ul style="list-style-type: none"><li>• High affinity for target</li><li>• Potential for multiple chelators (and radionuclides) per targeting agent</li><li>• Slower pharmacokinetics can impact radionuclide considerations</li><li>• Typically require transport mechanisms to cross BBB</li></ul>	<ul style="list-style-type: none"><li>• TLX591</li><li>• Iomab-B</li></ul>